PROVE—Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Interim Analysis in Pediatric Patients

Abstract

PROVE is a retrospective, phase IV study assessing retention, dosing, efficacy, and safety of perampanel when administered to patients during routine clinical care. We report an interim analysis of preadolescent (1 to <12 years) and adolescent (12 to <18 years) patients. Data were obtained from medical records of patients with epilepsy initiating perampanel after January 1, 2014; cut-off date for this analysis was October 10, 2018. Overall, 151 preadolescent and 183 adolescent patients were included. Retention rates following 24 months on perampanel were 42.5% (preadolescent subgroup; n = 31/73) and 55.7% (adolescent subgroup; n = 54/97). Treatment-emergent adverse events occurred in 53 (35.1%) preadolescent (most common: aggression, irritability, and somnolence) and 78 (42.6%) adolescent patients (most common: somnolence, aggression, and dizziness). These data indicate that daily oral doses of perampanel are generally well tolerated during routine clinical care, with favorable retention rates for ≤2 years, in patients aged 1 to <18 years.

Keywords

adolescents antiseizure drugs children efficacy epilepsy pediatric seizures

Get full access to this article

View all access options for this article.

References

European Medicines Agency. Fycompa® Annex I: Summary of Product Characteristics, July 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf. Accessed November 26, 2020.

Food and Drug Administration. Fycompa® Prescribing Information, September 2020. Available at: https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed November 26, 2020.

French

Krauss

Biton

, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589-596.

French

Krauss

Steinhoff

, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117-125.

Krauss

Serratosa

Villanueva

, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415.

Nishida

Lee

Inoue

Saeki

Ishikawa

Kaneko

. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137(4):392-399.

French

Krauss

Wechsler

, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85(11):950-957.

Flamini

Patten

Ngo

. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with partial-onset seizures or primary generalized tonic-clonic seizures in Study 311. Poster 007. Poster presented at: the 72nd Annual Meeting of the American Academy of Neurology, Toronto, Canada, May 2020.

Piña-Garza

Rosenfeld

Saeki

, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav. 2020;104(Pt A): 106876.

10.

Krauss

Perucca

Ben-Menachem

, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7): 1058-1068.

11.

Clinicaltrials.gov. A efficacy and safety study of adjunctive perampanel in primary generalized tonic clonic seizures [updated August 28, 2017]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01393743. Accessed November 26, 2020.

12.

Piña-Garza

Lagae

Villanueva

, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83: 50-58.

13.

Renfroe

Mintz

Davis

, et al. Adjunctive perampanel oral suspension in pediatric patients from >/=2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy. J Child Neurol. 2019;34(5): 284-294.

14.

Makady

de Boer

Hillege

Klungel

Goettsch

. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-865.

15.

French

. Trial design: how do we figure out if an AED works. Epilepsy Curr. 2012;12(1): 24-26.

16.

Wechsler

Wheless

Lancman

Aboumatar

Patten

Malhotra

. Perampanel in real-world clinical care of patients with epilepsy: retrospective phase IV PROVE Study 506. Poster 22. Poster presented at the 12th International Epilepsy Colloquium, Lyon, France, 26–28 May 2019.

17.

Segal

Wheless

Moretz

Penovich

Patten

Malhotra

. PROVE Study 506 – a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years). Poster 23. Poster presented at the 12th International Epilepsy Colloquium, Lyon, France, 26-28 May 2019.

18.

Brandt

Wechsler

O’Brien

, et al. Adjunctive perampanel and myoclonic and absence seizures: post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure. 2020;80: 115-123.

19.

Ettinger

LoPresti

Yang

, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetetive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8): 1252-1263.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.75 MB